ΔznuAΔpurE Brucella abortus 2308 mutant as a live vaccine candidate

Vaccine

Volumn 28, Issue 4, 2010, Pages 1069-1074

  Yang, Xinghong ^a   Thornburg, Theresa ^a   Walters, Nancy ^a   Pascual, David W ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Brucellosis; Live vaccine; Macrophages

Indexed keywords

BRUCELLA VACCINE; LIVE VACCINE; BACTERIAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM MUTANT; BRUCELLA ABORTUS; BRUCELLOSIS; CONTROLLED STUDY; FEMALE; GENE DELETION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MICROBIAL VIABILITY; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; VACCINATION; VIRULENCE;

ANIMALS; BACTERIAL PROTEINS; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; FEMALE; GENE DELETION; IMMUNIZATION, SECONDARY; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; SPLEEN; VACCINATION; VACCINES, ATTENUATED; VIRULENCE;

EID: 73949130985     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.113     Document Type: Article

References (40)

1. Corbel M. Brucellosis: an overview. Emerg Infect Dis 3 (1997) 213-221
2. Cutler S.J., Whatmore A.M., and Commander N.J. Brucellosis-new aspects of an old disease. J Appl Microbiol (2005) 981270-981281
3. Godfroid J., Cloeckaert A., Liautard J.P., Kohler S., Fretin D., Walravens K., et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 36 (2005) 313-326
4. Meador V.P., and Deyoe B.L. Intracellular localization of Brucella abortus in bovine placenta. Vet Pathol 26 (1989) 513-515
5. Enright F.M. The pathogenesis and pathobiology of Brucella infection in domestic animals. In: Duncan J.R. (Ed). Animal brucellosis (1990), CRC Press, Boca Raton, FL 301-320
6. Hong C.B., Donahue J.M., Giles R.C., Poonacha K.B., Tuttle P.A., and Cheville N.F. Brucella abortus-associated meningitis in aborted bovine fetuses. Vet Pathol 28 (1991) 492-496
7. Meng X.J., Lindsay D.S., and Sriranganathan N. Wild boars as sources for infectious diseases in livestock and humans. Philos Trans R Soc Lond B Biol Sci 364 (2009) 2697-2707
8. Arenas-Gamboa A.M., Ficht T.A., Kahl-McDonagh M.M., Gomez G., and Rice-Ficht A.C. The Brucella abortus S19 ΔvjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun 77 (2009) 877-884
9. Moriyon I., Grillo M.J., Monreal D., Gonzalez D., Marin C., Lopez-Goni I., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 35 (2004) 1-38
10. Blasco J.M. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 31 (1997) 275-283
11. Wallach J.C., Ferrero M.C., Delpino M.V., Fossati C.A., and Baldi P.C. Occupational infection due to Brucella abortus S19 among workers involved in vaccine production in Argentina. Clin Microbiol Infect 14 (2008) 805-807
12. Nicoletti P. Vaccination against Brucella. Adv Biotechnol Processes 13 (1990) 147-168 [review]
13. Schurig G.G., Sriranganathan N., and Corbel M.J. Brucellosis vaccines: past, present and future. Vet Microbiol 90 (2002) 479-496
14. Lord V.R., Schurig G.G., Cherwonogrodzky J.W., Marcano M.J., and Melendez G.E. Field study of vaccination of cattle with Brucella abortus strains RB51 and 19 under high and low disease prevalence. Am J Vet Res 59 (1998) 1016-1020
15. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., and Sriranganathan N. Biological properties of RB51-a stable rough strain of Brucella abortus. Vet Microbiol 28 (1991) 171-188
16. Adone R., Ciuchini F., Marianelli C., Tarantino M., Pistoia C., Marcon G., et al. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun 73 (2005) 4198-4204
17. Cheville N.F., Olsen S.C., Jensen A.E., Stevens M.G., Palmer M.V., and Florance A.M. Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. Am J Vet Res 57 (1996) 1153-1156
18. Olsen S.C., Bricker B., Palmer M.V., Jensen A.E., and Cheville N.F. Responses of cattle to two dosages of Brucella abortus strain RB51: serology, clearance and efficacy. Res Vet Sci 66 (1999) 101-105
19. Elzer P.H., Enright F.M., Colby L., Hagius S.D., Walker J., Fatemi M.B., et al. Protection against infection and abortion induced by virulent challenge exposure after oral vaccination of cattle with Brucella abortus strain RB51. Am J Vet Res 59 (1998) 1575-1578
20. Poester F.P., Goncalves V.S., Paixão T.A., Santos R.L., Olsen S.C., Schurig G.G., et al. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine 24 (2006) 5327-5334
21. Entessar F., Ardalan A., Ebadi A., and Jones L.M. Effect of living Rev 1 vaccine in producing long-term immunity against Brucella melitensis infection in sheep in Iran. J Comp Pathol 77 (1967) 367-376
22. Galey F., Bousman J., Cleveland T., Etchpare J., Hendry R., Hines J., et al. Wyoming brucellosis coordination team report and recommendations (2005), University of Wyoming, Laramie, Wyoming
23. USDA:APHIS. 2007 animal health report; 2008.
24. Kim S., Watanabe K., Shirahata T., and Watarai M. Zinc uptake system (znuA locus) of Brucella abortus is essential for intracellular survival and virulence in mice. J Vet Med Sci 66 (2004) 1059-1063
25. Yang X.H., Becker T., Walters N., and Pascual D.W. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infect Immun 74 (2006) 3874-3879
26. Alcantara R.B., Read R.D.A., Valderas M.W., Brown T.D., and Roop R.M. Intact purine biosynthesis pathways are required for wild-type virulence of Brucella abortus 2308 in the BALB/c mouse model. Infect Immun 72 (2004) 4911-4917
27. Monreal D., Grillo M.J., Gonzalez D., Marin C.M., De Miguel M.J., Lopez-Goni I., et al. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun 71 (2003) 3261-3271
28. Stevens M.G., Olsen S.C., Pugh G.W., and Palmer M.V. Immune and pathological responses in mice infected with Brucella abortus-19 Brucella abortus-RB51, or Brucella abortus-2308. Infect Immun 62 (1994) 3206-3212
29. Crawford R.M., VandeVerg L., Yuan L., Hadfield T.L., Warren R.L., Drazek E.S., et al. Deletion of purE attenuates Brucella melitensis infection in mice. Infect Immun 64 (1996) 2188-2192
30. Sanchez D.O., Zandomeni R.O., Cravero S., Verdun R.E., Pierrou E., Faccio P., et al. Gene discovery through genomic sequencing of Brucella abortus. Infect Immun 69 (2001) 865-868
31. Halling S.M., Peterson-Burch B.D., Bricker B.J., Zuerner R.L., Qing Z., Li L.L., et al. Completion of the genome sequence of Brucella abortus and comparison to the highly similar genomes of Brucella melitensis and Brucella suis. J Bacteriol 187 (2005) 2715-2726
32. Patzer S.I., and Hantke K. The znuABC high-affinity zinc uptake system and its regulator Zur in Escherichia coli. Mol Microbiol 28 (1998) 1199-1210
33. Harmon B.G., Adams L.G., and Frey M. Survival of rough and smooth strains of Brucella abortus in bovine mammary gland macrophages. Am J Vet Res 49 (1998) 1092-1097
34. Liautard J.P., Gross A., Dornald J., and Kohler S. Interactions between professional phagocytes and Brucella spp. Microbiologia 12 (1996) 197-206
35. Gee J.M., Valderas M.W., Kovach M.E., Grippe V.K., Robertson G.T., Ng W.L., et al. The Brucella abortus Cu, Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infect Immun 73 (2005) 2873-2880
36. Cheville N.F., Olsen S.C., Jensen A.E., Stevens M.G., Florance A.M., Houng H.S., et al. Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16 M strain of Brucella melitensis. Infect Immun 64 (1996) 2431-2439
37. Hoover D.L., Crawford R.M., Van de Verg L.L., Izadjoo M.J., Bhattacharjee A.K., Paranavitana C.M., et al. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201 (16 M ΔpurEK). Infect Immun 67 (1999) 5877-6784
38. Ko J.Y., and Splitter G.A. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev 16 (2003) 65-78
39. Grillo M.J., Bosseray N., and Blasco J.M. In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologic 28 (2000) 119-127
40. Stevens M.G., Olsen S.C., Pugh G.W., and Brees D. Comparison of immune-responses and resistance to brucellosis in mice vaccinated with Brucella abortus-19 or RB51. Infect Immun 63 (1995) 264-270